| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH COMMUNICATION |
1 From the Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston (DM, SEH, WCW, and EBR); the Departments of Nutrition (DM, TP, WCW, and EBR) and Epidemiology (DM, SEH, KJ, WCW, and EBR), Harvard School of Public Health, Boston; the Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle (DM); the Franz-Volhard-Clinic, Charité, Humboldt University, Berlin (TP); the Department of Laboratory Medicine, Children’s Hospital and Harvard Medical School, Boston (NR); and the Department of Oral Health Policy and Epidemiology, Harvard School of Dental Medicine, Boston (KJ).
2 Supported by research grants [HL24074, HL34594, CA40356, DK46200 (Nurses’ Health Study, NHS) and CA50385 (NHSII)] and a nutrition training grant [T32DK07703 (NHS)] from the National Institutes of Health. Measurements of C-reactive protein were partially funded by research grant DE12102 (NHS); measurements of soluble tumor necrosis factor 
receptors were supported by an unrestricted grant from Merck. Support for DM was provided in part by a Health Services Research & Development fellowship at the Veterans Affairs Puget Sound Health Care System and by a National Research Service Award Training Grant in Academic Nutrition (DK07703).
3 Reprints not available. Address correspondence to D Mozaffarian, 665 Huntington Avenue, Building 2, Room 315, Boston, MA 02115. E-mail: darymd{at}hotmail.com.
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Objective: We investigated the relations between TFA intake and inflammatory markers.
Design: In 823 generally healthy women in the Nurses’ Health Study I and II, concentrations of soluble tumor necrosis factor receptors 1 and 2 (sTNF-R1, sTNF-R2), interleukin 6 (IL-6), and C-reactive protein (CRP) were measured. Usual dietary intakes assessed from 2 semiquantitative food-frequency questionnaires were averaged for each subject.
Results: In age-adjusted analyses, TFA intake was positively associated with sTNF-R1 and sTNF-R2 (P for trend < 0.001 for each): sTNF-R1 and sTNF-R2 concentrations were 10% (+108 pg/mL; 95% CI: 50, 167 pg/mL) and 12% (+258 pg/mL; 138, 377 pg/mL) higher, respectively, in the highest intake quintile than in the lowest. These associations were not appreciably altered by adjustment for body mass index, smoking, physical activity, aspirin and nonsteroidal antiinflammatory drug use, alcohol consumption, and intakes of saturated fat, protein, n-6 and n-3 fatty acids, fiber, and total energy. Adjustment for serum lipid concentrations partly attenuated these associations, which suggests that they may be partly mediated by effects of TFAs on serum lipids. TFA intake was not associated with IL-6 or CRP concentrations overall but was positively associated with IL-6 and CRP in women with higher body mass index (P for interaction = 0.03 for each).
Conclusions: TFA intake is positively associated with markers of systemic inflammation in women. Further investigation of the influences of TFAs on inflammation and of implications for coronary disease, diabetes, and other conditions is warranted.
Key Words: trans Fatty acids • diet • inflammation • tumor necrosis factor receptors • women
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Systemic inflammatory activation is an emerging risk factor for coronary artery disease, insulin resistance, diabetes, dyslipidemia, and heart failure. In both healthy persons and persons with coronary artery disease, elevated C-reactive protein (CRP) concentrations independently predict poor outcomes (6, 7). Elevated interleukin 6 (IL-6) concentrations are associated with insulin resistance, lipid abnormalities, coronary artery disease risk, and heart failure mortality (8–12). CRP and IL-6 concentrations also predict incident diabetes (13). Soluble tumor necrosis factor receptors 1 and 2 (sTNF-R1 and sTNF-R2)—which in their natural monomeric form increase the half-life and bioavailability of TNF, reflecting TNF system activation (14–17)—and their gene polymorphisms are independently associated with insulin resistance, diabetes, lipid abnormalities, coronary artery disease, and heart failure mortality (11, 16–24).
Thus, systemic inflammatory activation as measured by CRP, IL-6, sTNF-R1, and sTNF-R2 is integrally related to coronary artery disease, the metabolic syndrome, and heart failure. TFA intake also predicts risks of coronary disease and diabetes, but the mechanisms of these observed elevated risks are not well established. We wondered whether TFAs influence systemic inflammation, which might then partly account for the relations between TFAs and these conditions. We therefore investigated the associations between TFA intake and concentrations of CRP, IL-6, sTNF-R1, and sTNF-R2 in 823 generally healthy women enrolled in the Nurses’ Health Study (NHS) and Nurses’ Health Study II (NHSII).
|
SUBJECTS AND METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
The present analysis used data from NHS participants who were selected as control subjects for a study of myocardial infarction (MI) and from NHSII participants who were selected for a study on alcohol consumption (27). In the NHS, 498 participants were randomly selected as control subjects for women with incident MI, and the controls were matched to the cases on age, smoking, and blood-draw characteristics. Potential control subjects were excluded if they had a history of MI, angina, coronary revascularization, stroke, or nonmelanoma cancer at the time of blood collection (1989–1990). Body mass index (BMI; in kg/m2), smoking habits, alcohol consumption, and use of medications were assessed from the 1990 questionnaire; physical activity was assessed from the 1988 questionnaire because the 1990 questionnaire assessed only walking and stair climbing (25–29). These women were similar to the overall NHS cohort except for being older (61.2 y compared with 57.4 y) and more likely to be a current smoker (20% compared with 13%) due to matching criteria. We excluded 16 women with diabetes and 109 women with missing data on diet, inflammatory markers, BMI, smoking, or physical activity, and thus 373 NHS participants were included in this analysis.
In the NHSII, 473 premenopausal participants were randomly selected, stratified by alcohol drinking patterns (frequency, amount, with or without meals), for a study on alcohol consumption (27). Women were excluded if they were taking hormones or had a history of MI, angina, stroke, diabetes, intermittent claudication, peptic ulcer disease, gallbladder or liver disease, or nonmelanoma cancer at the time of blood collection (1996–1998). BMI, physical activity, smoking habits, alcohol consumption, and medication use were assessed from the 1997 questionnaire (25–29). These women were similar to the overall NHSII cohort except for having a greater average alcohol intake (11.4 compared with 3.5 g/d) due to the selection criteria. We excluded 23 women with missing data on diet, inflammatory markers, BMI, smoking, or physical activity, and thus 450 NHSII participants were included in this analysis.
Dietary assessment
To minimize misclassification, usual dietary intakes assessed from 2 semiquantitative food-frequency questionnaires that were closest in time to the blood draw were averaged for each participant (1986 and 1990 in NHS; 1995 and 1999 in NHSII). The reproducibility and validity of this food-frequency questionnaire have been described previously (30–32). The participants were asked to indicate how often, on average, they had consumed given amounts of various specified foods during the past year. Intakes of TFAs and other nutrients were computed by using composition values from the US Department of Agriculture (33) and the Harvard University Food Composition Database, including specific information on the types and brands of margarines, fats, and oils used by each subject for frying, cooking, and baking. Nutrient intakes were preadjusted for total energy by using separate regression analyses (34). Correlation coefficients between the estimates of intake of total fat and types of fat from the food-frequency questionnaire and the averge of 4 one-week dietary records ranged from 0.48 to 0.68 (32). The correlation between the calculated dietary TFA intake from the food-frequency questionnaire and the proportion of TFAs in adipose tissue was 0.51 (32). The range of reported total energy intake was 763–3368 kcal/d.
Measurement of inflammatory markers
CRP concentrations were measured spectrophotometrically by using a high-sensitivity assay (Hitachi 911 analyzer; Roche Diagnostics, Indianapolis) with reagents and calibrators from Denka Seiken (Niigata, Japan); day-to-day CVs were 9.4% and 1.1% at 0.65 and 13.4 mg/L, respectively. IL-6 concentrations were measured with an ultrasensitive enzyme-linked immunosorbent assay (R&D Systems, Minneapolis) with a sensitivity of 0.094 pg/mL and CVs of 12%, 15%, 7%, and 7% at 0.67, 1.4, 2.69, and 7.48 pg/mL, respectively. sTNF-R1 and sTNF-R2 concentrations were measured with enzyme-linked immunosorbent assays (R&D Systems) with CVs of 8.7% and 9.3%, respectively. Processing times did not substantially affect concentrations of these inflammatory markers (35). Intraclass correlations over a period of 4 y were 0.7 for CRP, 0.5 for IL-6, and 0.8 for sTNF-R1 and sTNF-R2 (36).
Statistical analysis
Linear regression with robust variance estimates (accounting for heteroscedasticity) (37) was used to evaluate associations between TFA intake and concentrations of sTNF-R1, sTNF-R2, IL-6, and CRP; analyses were also repeated by using log-transformed concentrations. TFA intake was evaluated in quintiles as a percentage of total fat intake; analyses were also repeated with TFA intake evaluated as a percentage of total energy or after adjustment for total energy by using regression. Tests for linear trend were calculated by assigning the median value for each quintile of intake treated as a continuous variable. All results were age adjusted (5-y categories). To assess for confounding, 2 prespecified models were evaluated: 1) adjusted for age, BMI (5 categories), smoking (4 categories), and physical activity (quintiles); and 2) further adjusted for aspirin use, nonsteroidal antiinflammatory drug use, alcohol use (5 categories), and consumption of saturated fat, protein, n-6 polyunsaturated fat, n-3 polyunsaturated fat, fiber, and total energy (each in quintiles). We also evaluated associations after adjustment for LDL and HDL cholesterol, triacylglycerols, and lipoprotein(a) (each in quintiles) to assess potential mediation and confounding by these serum lipoproteins. Potential effect modification was evaluated for age, BMI, and aspirin use (prespecified) and for n-6 fatty acid consumption and nonsteroidal antiinflammatory drug use (post hoc) by using multiplicative (continuous) interaction terms and likelihood ratio testing. Relations were initially evaluated separately in the NHS and the NHSII; analyses were then performed on the combined dataset. Analyses were performed by using SAS 8.2 (SAS Institute Inc, Cary, NC). All P values are two-tailed ( = 0.05).
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
TFA intake was inversely associated with physical activity, HDL cholesterol, and intakes of alcohol, protein, n-3 fatty acids, and dietary fiber and was positively associated with BMI and the ratio of LDL to HDL cholesterol (Table 1
). Assessed as a percentage of total fat intake, TFA intake was not associated with the intakes of saturated fat or n-6 fatty acids, thus minimizing potential confounding by these dietary factors.
|
). These relations were not greatly altered by adjustment for other factors that might influence inflammation, including BMI, smoking, and physical activity (model 1; P for trend = 0.001 for sTNF-R1, and P for trend < 0.001 for sTNF-R2) and medication use and dietary factors (model 2; P for trend = 0.002 for sTNF-R1, and P for trend < 0.001 for sTNF-R2). In similar analyses, TFA intake was not associated with CRP or IL-6 concentrations (Table 2). Results were not appreciably different when inflammatory marker concentrations were log transformed before evaluation (data not shown).
|
We evaluated how different food groups contributing to TFA intake related to sTNF-R1 and sTNF-R2 concentrations (Table 3). After adjustment for potential confounders, each serving of margarine/d was associated with trends toward higher concentrations of sTNF-R1 (+26 pg/mL; 95% CI: -1, 53 pg/mL) and sTNF-R2 (+28 pg/mL; 95% CI: -24, 80 pg/mL). However, there were no significant associations, and broad CIs limited detection of potential relations.
|
When we evaluated potential interactions, TFA intake was positively associated with IL-6 and CRP concentrations in women with higher BMI (P for interaction = 0.03 for each): higher TFA intake (each 1% of dietary fat) was associated with 0.06-pg/mL (95% CI: 0.01, 0.11 pg/mL) higher IL-6 concentrations and 0.09-mg/L (95% CI: 0.01, 0.17 pg/mL) higher CRP concentrations for each 1 unit of higher BMI (adjustments as in model 2). There was little evidence that relations between TFA intake and sTNF-R1 or sTNF-R2 varied according to BMI or that relations between TFA intake and any of the inflammatory markers varied according to age, aspirin use, nonsteroidal antiinflammatory drug use, or n-6 fatty acid intake (P > 0.15 for each interaction). The findings were not appreciably different if TFA intake was evaluated as a percentage of total energy or after adjustment for total energy by using regression (data not shown).
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Although administration of dimeric Fc fusion constructs of the TNF receptor or of high concentrations of natural monomeric sTNF-R1 and sTNF-R2 competitively inhibits TNF activity, at physiologic concentrations sTNF-R1 and sTNF-R2 prevent TNF decay, preserving the active form of TNF and increasing TNF bioavailability (14, 15). Thus, concentrations of endogenously produced sTNF-R1 and sTNF-R2 reflect the activity of the TNF system (16, 17), and concentrations of these receptors correlate with numerous disease states including coronary artery disease, diabetes, and heart failure (11, 16–24). Our results show higher sTNF-R1 and sTNF-R2 concentrations with higher TFA intake, indicating a link between TFA intake and TNF activity. These findings are consistent with those of an experimental study in 19 subjects in which consumption of a soybean margarine diet (6.7% of energy from TFAs) increased TNF production by cultured mononuclear cells in comparison with consumption of a soybean oil diet (0.6% of energy from TFAs) (38).
The associations of TFA consumption with coronary artery disease risk reported in prior studies are greater than would be predicted by effects on serum lipoproteins alone (3). In our study, relations between TFA intake and TNF receptor concentrations were only partly attenuated by adjustment for serum lipid concentrations, suggesting that this relation is not wholly mediated through effects on serum lipids. In experimental studies, TFAs also increase insulin resistance, reduce postprandial tissue plasminogen activator activity, impair endothelial cell function, and increase lipid oxidation (39–42). Each of these abnormalities can be caused by activation of the TNF system (43–47). The TNF system may also promote atherosclerosis via effects on plaque stability, endothelial cell permeability and receptors, and monocyte and macrophage activation (48, 49). In addition, TFA intake is associated with an elevated risk of new-onset diabetes (4), and activation of the TNF system is a risk factor for diabetes, independent of adiposity (22, 23). Thus, activation of the TNF system may represent a mediating step between TFA consumption and risks of coronary artery disease and diabetes.
In the present study, trans 16:1 was not associated with TNF receptor concentrations. In contrast, trans 18:2 and trans 18:1—the predominant TFA in the diet and generally consumed from margarine, partially hydrogenated vegetable oils, and bakery sweets—each predicted higher TNF receptor concentrations. Among the different food groups, margarine tended to be associated with higher TNF receptor concentrations; CIs were broad, however, for each of the food groups. These potential differences in the influence of different trans isomers and different foods on the TNF system require confirmation in additional studies and should be viewed as hypothesis generating. Interestingly, trans 18:1 and trans 18:2 are stronger predictors of sudden cardiac death than is trans 16:1 (50).
How might TFA consumption influence inflammation? TFAs are incorporated into endothelial cell membranes (51), which have numerous cell-specific pathways relating to TNF activation (49). TFAs may also modulate TNF biology via effects on macrophage membrane phospholipids and signaling pathways, in a manner analogous to mechanisms seen with n-3, n-6, and monounsaturated fatty acids (52). Thus, there are biologically plausible mechanisms for an association between TFA intake and activation of the TNF system. Furthermore, although we did not observe an association between TFA intake and IL-6 or CRP concentrations overall, higher TFA intake predicted higher IL-6 and CRP concentrations in women with higher BMI. IL-6 and CRP are both linked to adiposity and the metabolic syndrome, which may be related to the production and release of IL-6 by adipose tissue (53). Thus, our findings raise the biologically interesting hypothesis that women with higher BMI may be more susceptible to effects of TFA intake on IL-6 and CRP production, which may be related to effects on or responses of adipose tissue. Further investigation of these relations, including the potential mechanisms of effect, is warranted.
Our study had several strengths. TFA intake was estimated by using a well-established, validated dietary instrument. Exclusion of women with known significant medical conditions at baseline reduced potential bias from changes in diet due to known disease. Standardized assessment of other participant characteristics increased our ability to adjust for potential confounding factors.
Our findings also have potential limitations. TFA intake was likely estimated with some error due to imperfect estimates of the intakes of specific foods and of their TFA content due to variation in preparation methods and manufacturing processes. In addition, if inflammation is influenced by short-term (days to weeks) rather than long-term (months to years) TFA intake, there may have been misclassification because of variation from the usual diet at the time of blood collection. (On the other hand, the half-life of specific fatty acids in adipose tissue is several months; thus, effects of TFAs in short-term studies could be underestimated or missed entirely.) Thus, potential measurement error in exposure and outcomes may have led to underestimation of the true relations between TFA intake and the inflammatory markers; for example, this may in part explain the lack of observed associations between TFA intake and IL-6 and CRP overall. Although we adjusted for various clinical and dietary characteristics, residual confounding due to unmeasured or incompletely measured factors cannot be excluded. The women in our study were generally healthy women participating in a longitudinal cohort study, and our findings may not be generalizable to other populations.
Our results suggest that dietary intake of TFAs is associated with systemic inflammation in generally healthy women, as reflected by higher TNF receptor concentrations, as well as higher IL-6 and CRP concentrations in women with higher BMI, and that these associations are independent of various other characteristics including serum lipid concentrations. This observed relation between TFA intake and systemic inflammation may represent a novel potential mechanism for the effects of TFAs on risks of coronary artery disease and diabetes. Further study is indicated to investigate the potential proinflammatory effects of TFAs and the implications of such effects for risks of coronary artery disease, diabetes, and other conditions.
|
ACKNOWLEDGMENTS |
|---|
DM contributed to the study design, analysis, and manuscript preparation. TP contributed to data interpretation and manuscript preparation. SEH, NR, KJ, and WCW contributed to data collection, data interpretation, and manuscript preparation. EBR contributed to the study design, data collection, data interpretation, and manuscript preparation. None of the authors had any conflicts of interest.
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  C. Puiggros, J. Sanchez, P. Chacon, P. Sabin, J. Rosello, R. Bou, and M. Planas Evolution of Lipid Profile, Liver Function, and Pattern of Plasma Fatty Acids According to the Type of Lipid Emulsion Administered in Parenteral Nutrition in the Early Postoperative Period After Digestive Surgery JPEN J Parenter Enteral Nutr, September 1, 2009; 33(5): 501 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A Nettleton, A. Diez-Roux, N. S Jenny, A. L Fitzpatrick, and D. R Jacobs Jr Dietary patterns, food groups, and telomere length in the Multi-Ethnic Study of Atherosclerosis (MESA) Am. J. Clinical Nutrition, November 1, 2008; 88(5): 1405 - 1412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Esmaillzadeh and L. Azadbakht Home use of vegetable oils, markers of systemic inflammation, and endothelial dysfunction among women Am. J. Clinical Nutrition, October 1, 2008; 88(4): 913 - 921. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. Vinikoor, J. C. Schroeder, R. C. Millikan, J. A. Satia, C. F. Martin, J. Ibrahim, J. A. Galanko, and R. S. Sandler Consumption of trans-Fatty Acid and Its Association with Colorectal Adenomas Am. J. Epidemiol., August 1, 2008; 168(3): 289 - 297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A Nettleton, M. B Schulze, R. Jiang, N. S Jenny, G. L Burke, and D. R Jacobs Jr A priori-defined dietary patterns and markers of cardiovascular disease risk in the Multi-Ethnic Study of Atherosclerosis (MESA) Am. J. Clinical Nutrition, July 1, 2008; 88(1): 185 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Esmaillzadeh and L. Azadbakht Consumption of Hydrogenated Versus Nonhydrogenated Vegetable Oils and Risk of Insulin Resistance and the Metabolic Syndrome Among Iranian Adult Women Diabetes Care, February 1, 2008; 31(2): 223 - 226. [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Chavarro, M. J. Stampfer, H. Campos, T. Kurth, W. C. Willett, and J. Ma A Prospective Study of Trans-Fatty Acid Levels in Blood and Risk of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 95 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. K. Kabagambe, M. Y. Tsai, P. N. Hopkins, J. M. Ordovas, J. M. Peacock, I. B. Borecki, and D. K. Arnett Erythrocyte Fatty Acid Composition and the Metabolic Syndrome: A National Heart, Lung, and Blood Institute GOLDN Study Clin. Chem., January 1, 2008; 54(1): 154 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rodriguez-Sallaberry, C. Caldari-Torres, W. Collante, C. R. Staples, and L. Badinga Plasma Prostaglandin and Cytokine Concentrations in Periparturient Holstein Cows Fed Diets Enriched in Saturated or Trans Fatty Acids J Dairy Sci, December 1, 2007; 90(12): 5446 - 5452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kreimer A Provider Primer on Omega-3 DOC News, September 1, 2007; 4(9): 6 - 6. [Full Text]
|
|
|
|
 |
|
 M. L. Neuhouser, M. J. Barnett, A. R. Kristal, C. B. Ambrosone, I. King, M. Thornquist, and G. Goodman (n-6) PUFA Increase and Dairy Foods Decrease Prostate Cancer Risk in Heavy Smokers J. Nutr., July 1, 2007; 137(7): 1821 - 1827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Liu, F. R. Schumacher, S. J. Plummer, E. Jorgenson, G. Casey, and J. S. Witte trans-Fatty acid intake and increased risk of advanced prostate cancer: modification by RNASEL R462Q variant Carcinogenesis, June 1, 2007; 28(6): 1232 - 1236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Esmaillzadeh, M. Kimiagar, Y. Mehrabi, L. Azadbakht, F. B. Hu, and W. C. Willett Dietary Patterns and Markers of Systemic Inflammation among Iranian Women J. Nutr., April 1, 2007; 137(4): 992 - 998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E Chavarro, J. W Rich-Edwards, B. A Rosner, and W. C Willett Dietary fatty acid intakes and the risk of ovulatory infertility Am. J. Clinical Nutrition, January 1, 2007; 85(1): 231 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kuhnt, A. Wagner, J. Kraft, S. Basu, and G. Jahreis Dietary supplementation with 11trans- and 12trans-18:1 and oxidative stress in humans. Am. J. Clinical Nutrition, November 1, 2006; 84(5): 981 - 988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. Willett and F. B. Hu Not the Time to Abandon the Food Frequency Questionnaire: Point Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1757 - 1758. [Full Text] [PDF]
|
|
|
|
|
|
R. Friesen and S. M. Innis Trans Fatty Acids in Human Milk in Canada Declined with the Introduction of Trans Fat Food Labeling J. Nutr., October 1, 2006; 136(10): 2558 - 2561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Giugliano, A. Ceriello, and K. Esposito The Effects of Diet on Inflammation: Emphasis on the Metabolic Syndrome J. Am. Coll. Cardiol., August 15, 2006; 48(4): 677 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Lemaitre, I. B. King, D. Mozaffarian, N. Sotoodehnia, T. D. Rea, L. H. Kuller, R. P. Tracy, and D. S. Siscovick Plasma Phospholipid Trans Fatty Acids, Fatal Ischemic Heart Disease, and Sudden Cardiac Death in Older Adults: The Cardiovascular Health Study Circulation, July 18, 2006; 114(3): 209 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A Nettleton, L. M Steffen, E. J Mayer-Davis, N. S Jenny, R. Jiang, D. M Herrington, and D. R Jacobs Jr Dietary patterns are associated with biochemical markers of inflammation and endothelial activation in the Multi-Ethnic Study of Atherosclerosis (MESA) Am. J. Clinical Nutrition, June 1, 2006; 83(6): 1369 - 1379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mozaffarian, M. B. Katan, A. Ascherio, M. J. Stampfer, and W. C. Willett Trans Fatty Acids and Cardiovascular Disease N. Engl. J. Med., April 13, 2006; 354(15): 1601 - 1613. [Full Text] [PDF]
|
|
|
|
|
|
S. E Kasim-Karakas, A. Tsodikov, U. Singh, and I. Jialal Responses of inflammatory markers to a low-fat, high-carbohydrate diet: effects of energy intake. Am. J. Clinical Nutrition, April 1, 2006; 83(4): 774 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tholstrup, M. Raff, S. Basu, P. Nonboe, K. Sejrsen, and E. M Straarup Effects of butter high in ruminant trans and monounsaturated fatty acids on lipoproteins, incorporation of fatty acids into lipid classes, plasma C-reactive protein, oxidative stress, hemostatic variables, and insulin in healthy young men Am. J. Clinical Nutrition, February 1, 2006; 83(2): 237 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. B. King, A. R. Kristal, S. Schaffer, M. Thornquist, and G. E. Goodman Serum Trans-Fatty Acids Are Associated with Risk of Prostate Cancer in {beta}-Carotene and Retinol Efficacy Trial Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 988 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Lopez-Garcia, M. B. Schulze, J. B. Meigs, J. E. Manson, N. Rifai, M. J. Stampfer, W. C. Willett, and F. B. Hu Consumption of Trans Fatty Acids Is Related to Plasma Biomarkers of Inflammation and Endothelial Dysfunction J. Nutr., March 1, 2005; 135(3): 562 - 566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Mozaffarian, E. B Rimm, I. B King, R. L Lawler, G. B McDonald, and W. C Levy trans Fatty acids and systemic inflammation in heart failure Am. J. Clinical Nutrition, December 1, 2004; 80(6): 1521 - 1525. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
